{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:29:59Z","timestamp":1762507799904,"version":"3.41.2"},"reference-count":12,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1136\/ijgc-2019-000370","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T03:35:11Z","timestamp":1565926511000},"page":"1141-1147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer"],"prefix":"10.1016","volume":"29","clinical-trial-number":[{"clinical-trial-number":"nct01684878","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Domenica","family":"Lorusso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Hilpert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gonz\u00e1lez Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joern","family":"Rau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petronella","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elfriede","family":"Greimel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Joachim","family":"L\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Selle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith R","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor R","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Maria","family":"Grischke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Berton-Rigaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeronimo","family":"Martinez-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-8981","authenticated-orcid":false,"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydie","family":"Basti\u00e8re-Truchot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Kurzeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2019-000370_bb0010","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/IGC.0000000000000147","article-title":"Symptom burden and outcomes of patients with platinum resistant\/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the Gynecologic Cancer InterGroup Symptom Benefit Study","volume":"24","author":"Friedlander","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2019-000370_bb0015","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2015.66.0787","article-title":"Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE)","volume":"34","author":"Kurzeder","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000370_bb0020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2009.22.3354","article-title":"Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer","volume":"28","author":"Makhija","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000370_bb0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-000370_bb0030","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/IGC.0000000000000695","article-title":"Pertuzumab plus chemotherapy for platinum-resistant ovarian cancer: safety run-in results of the PENELOPE trial","volume":"26","author":"Gonz\u00e1lez-Mart\u00edn","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2019-000370_bb0035","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000370_bb0040","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000370_bb0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/annonc\/mds282","article-title":"A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer","volume":"24","author":"Kaye","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-000370_bb0050","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/annonc\/mdx229","article-title":"Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy","volume":"28","author":"Roncolato","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-000370_bb0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2017.03.019","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer","volume":"78","author":"Joly","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2019-000370_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11136-017-1729-8","article-title":"Measuring what matters most: validation of the measure of ovarian symptoms and treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer","volume":"27","author":"King","year":"2018","journal-title":"Qual Life Res"},{"issue":"Suppl 4","key":"10.1136\/ijgc-2019-000370_bb0065","first-page":"86","article-title":"Comparison of gene mutational analyses, including BRCA1 alterations, in two prospective studies in newly diagnosed versus platinum-resistant ovarian cancer","volume":"27","author":"Deurloo","year":"2017","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24002536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24002536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2019-000370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:37:00Z","timestamp":1753223820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24002536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1048891X24002536"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2019-000370","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2019-000370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}